

Bram L T Ramaekers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/375997/publications.pdf>

Version: 2024-02-01

70
papers

1,557
citations

361413

20
h-index

330143

37
g-index

72
all docs

72
docs citations

72
times ranked

3097
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer. <i>Acta Oncologica</i> , 2022, 61, 619-624. | 1.8 | 0 |
| 2 | Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2021, 39, 171-180. | 3.3 | 4 |
| 3 | Comment on "External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions" <i>Pharmacoeconomics</i> , 2021, 39, 133-135. | 3.3 | 1 |
| 4 | Prognostic and Predictive Value of Integrated Qualitative and Quantitative Magnetic Resonance Imaging Analysis in Glioblastoma. <i>Cancers</i> , 2021, 13, 722. | 3.7 | 24 |
| 5 | Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for) <i>Tj ETQq 2.1 0.784314 rgBT</i> | 1.7 | 14 |
| 6 | Modeling-Based Decision Support System for Radical Prostatectomy Versus External Beam Radiotherapy for Prostate Cancer Incorporating an In Silico Clinical Trial and a Cost-Utility Study. <i>Cancers</i> , 2021, 13, 2687. | 3.7 | 1 |
| 7 | High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2021, 25, 1-276. | 2.8 | 16 |
| 8 | Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2021, 158, 40-47. | 0.6 | 7 |
| 9 | State of the ART? Two New Tools for Risk Communication in Health Technology Assessments. <i>Pharmacoeconomics</i> , 2021, 39, 1185-1196. | 3.3 | 4 |
| 10 | Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study. <i>Value in Health</i> , 2021, 24, 983-994. | 0.3 | 7 |
| 11 | Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 1429-1442. | 3.3 | 10 |
| 12 | Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation. <i>Value in Health</i> , 2021, 24, 1126-1136. | 0.3 | 4 |
| 13 | Optimizing the Use of High-Sensitivity Troponin Assays for the Early Rule-out of Myocardial Infarction in Patients Presenting with Chest Pain: A Systematic Review. <i>Clinical Chemistry</i> , 2021, 67, 237-244. | 3.2 | 17 |
| 14 | Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials. <i>Radiotherapy and Oncology</i> , 2021, 164, 163-166. | 0.6 | 0 |
| 15 | Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study. <i>Radiotherapy and Oncology</i> , 2020, 144, 65-71. | 0.6 | 15 |
| 16 | Development and Validation of the TRansparent Uncertainty ASsessmentT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models. <i>Pharmacoeconomics</i> , 2020, 38, 205-216. | 3.3 | 23 |
| 17 | Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry. <i>Quality of Life Research</i> , 2020, 29, 3363-3374. | 3.1 | 11 |
| 18 | An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry. <i>Acta Oncologica</i> , 2020, 59, 1123-1130. | 1.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study. <i>Pharmacoeconomics</i> , 2020, 38, 765-776. | 3.3 | 6 |
| 20 | Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients â€” A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103035. | 4.4 | 5 |
| 21 | Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands. <i>PLoS ONE</i> , 2020, 15, e0230909. | 2.5 | 7 |
| 22 | Title is missing!. , 2020, 15, e0230909. | | 0 |
| 23 | Title is missing!. , 2020, 15, e0230909. | | 0 |
| 24 | Title is missing!. , 2020, 15, e0230909. | | 0 |
| 25 | Title is missing!. , 2020, 15, e0230909. | | 0 |
| 26 | Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 72-81. | 1.6 | 1 |
| 27 | Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 1195-1207. | 3.3 | 8 |
| 28 | Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments. <i>Quality of Life Research</i> , 2019, 28, 2257-2279. | 3.1 | 9 |
| 29 | Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 326-327. | 1.1 | 0 |
| 30 | Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 887-894. | 3.3 | 13 |
| 31 | Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?. <i>Value in Health</i> , 2019, 22, 799-807. | 0.3 | 14 |
| 32 | Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 655-667. | 3.3 | 8 |
| 33 | Telemonitoring in patients with heart failure: Is there a long-term effect?. <i>Journal of Telemedicine and Telecare</i> , 2019, 25, 158-166. | 2.7 | 10 |
| 34 | Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 917-927. | 3.3 | 7 |
| 35 | Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 533-543. | 3.3 | 2 |
| 36 | Trifluridineâ€”Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 285-288. | 3.3 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Development of an isotoxic decision support system integrating genetic markers of toxicity for the implantation of a rectum spacer. <i>Acta Oncologica</i> , 2018, 57, 1499-1505. | 1.8 | 6 |
| 38 | Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer. <i>European Journal of Cancer</i> , 2018, 100, 55-64. | 2.8 | 5 |
| 39 | EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 429-432. | 2.1 | 12 |
| 40 | Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research. <i>Pharmacoeconomics</i> , 2018, 36, 105-113. | 3.3 | 5 |
| 41 | The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation. <i>Frontiers in Oncology</i> , 2018, 8, 241. | 2.8 | 18 |
| 42 | Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2018, 22, 1-264. | 2.8 | 106 |
| 43 | Decision support systems for personalized and participative radiation oncology. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 131-153. | 13.7 | 113 |
| 44 | Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal". <i>Pharmacoeconomics</i> , 2017, 35, 665-667. | 3.3 | 0 |
| 45 | Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness. <i>Radiotherapy and Oncology</i> , 2017, 125, 107-112. | 0.6 | 23 |
| 46 | What is the impact of innovation on output in healthcare with a special focus on treatment innovations in radiotherapy? A literature review. <i>British Journal of Radiology</i> , 2017, 90, 20170251. | 2.2 | 13 |
| 47 | Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 485-498. | 2.5 | 8 |
| 48 | Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 191-202. | 3.3 | 8 |
| 49 | Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium. <i>Oncotarget</i> , 2017, 8, 79223-79233. | 1.8 | 21 |
| 50 | Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. <i>Radiotherapy and Oncology</i> , 2016, 121, 440-446. | 0.6 | 15 |
| 51 | Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. <i>Pharmacoeconomics</i> , 2016, 34, 315-322. | 3.3 | 19 |
| 52 | European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer. <i>European Journal of Cancer</i> , 2016, 63, 168-179. | 2.8 | 8 |
| 53 | Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer "Comparison of dose, toxicity and cost-effectiveness. <i>Radiotherapy and Oncology</i> , 2016, 118, 281-285. | 0.6 | 65 |
| 54 | ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis. <i>Health Technology Assessment</i> , 2016, 20, 1-178. | 2.8 | 34 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Spacers in radiotherapy treatment of prostate cancer: Is reduction of toxicity cost-effective?. Radiotherapy and Oncology, 2015, 114, 276-281. | 0.6 | 49 |
| 56 | Cost-Effectiveness of Reduced Waiting Time for Head and Neck Cancer Patients due to a Lean Process Redesign. Value in Health, 2015, 18, 587-596. | 0.3 | 9 |
| 57 | A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. Pharmacoeconomics, 2015, 33, 205-224. | 3.3 | 84 |
| 58 | High-sensitivity troponin assays for the early rule-out or diagnosis of acute myocardial infarction in people with acute chest pain: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2015, 19, 1-234. | 2.8 | 39 |
| 59 | Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2015, 19, 1-236. | 2.8 | 114 |
| 60 | H-TARGET model: Early technology assessment for next generation sequencing in oncology.. Journal of Clinical Oncology, 2015, 33, 6604-6604. | 1.6 | 0 |
| 61 | Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2014, 18, 1-166. | 2.8 | 42 |
| 62 | KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2014, 18, 1-132. | 2.8 | 66 |
| 63 | How Should We Deal with Patient Heterogeneity in Economic Evaluation: A Systematic Review of National Pharmacoeconomic Guidelines. Value in Health, 2013, 16, 855-862. | 0.3 | 35 |
| 64 | Acknowledging Patient Heterogeneity in Economic Evaluation. Pharmacoeconomics, 2013, 31, 111-123. | 3.3 | 55 |
| 65 | Protons in Head-and-Neck Cancer: Bridging the Gap of Evidence. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1282-1288. | 0.8 | 71 |
| 66 | Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small-Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2013, 8, 1295-1307. | 1.1 | 16 |
| 67 | Systematic review and meta-analysis of radiotherapy in various head and neck cancers: Comparing photons, carbon-ions and protons. Cancer Treatment Reviews, 2011, 37, 185-201. | 7.7 | 86 |
| 68 | The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. Oral Oncology, 2011, 47, 768-774. | 1.5 | 94 |
| 69 | Adherence Among Telemonitored Patients with Heart Failure to Pharmacological and Nonpharmacological Recommendations. Telemedicine Journal and E-Health, 2009, 15, 517-524. | 2.8 | 31 |
| 70 | Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. The Cochrane Library, 2009, , CD006158. | 2.8 | 41 |